Loading...
Market
Which milestone payment will Merck achieve from Hansoh for HS-10535 by 2025?
2
Resolution / Starting Odds
Milestone 1 • 25%
Milestone 2 • 25%
Milestone 3 • 25%
No milestone achieved • 25%
Merck's financial disclosures and official press releases
Story
Merck Licenses Oral GLP-1 Drug from Hansoh Pharma for Potential Cardiometabolic Benefits in $2 Billion Deal
Dec 18, 2024, 12:15 PM
Merck & Co. Inc. has entered into an exclusive global license agreement with Hansoh Pharma, a Chinese biopharmaceutical company, for the development, manufacture, and commercialization of HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with the potential for up to $1.9 billion in milestone payments and royalties on sales. Merck aims to leverage this deal to enhance its pipeline in cardiometabolic diseases, focusing on the potential of HS-10535 to provide cardiometabolic benefits beyond weight reduction. The transaction reflects Merck's strategy to augment its offerings in the growing obesity drug market, which is expected to reach over $100 billion annually by the early 2030s.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%